Brompheniramine Maleate, Pseudoephedrine Hydrochloride, (brompheniramine maleate, pseudoephedrine hydrochloride,) - Dosing, PA Forms & Info (2026)
logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutCareersContact UsSecurity
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Brompheniramine Maleate, Pseudoephedrine Hydrochloride, - Brompheniramine Maleate, Pseudoephedrine Hydrochloride, syrup

    Get your patient on Brompheniramine Maleate, Pseudoephedrine Hydrochloride, - Brompheniramine Maleate, Pseudoephedrine Hydrochloride, syrup (Brompheniramine Maleate, Pseudoephedrine Hydrochloride,)

    Medication interactionsSee all drug-to-drug interactions for this medication.
    card icon
    Prescribing informationPubMed™ news

    Brompheniramine Maleate, Pseudoephedrine Hydrochloride, - Brompheniramine Maleate, Pseudoephedrine Hydrochloride, syrup prescribing information

    • Indications & usage
    • Dosage & administration
    • Contraindications
    • Adverse reactions
    • Drug interactions
    • Description
    • Pharmacology
    • How supplied/storage & handling
    • Data source
    • Indications & usage
    • Dosage & administration
    • Contraindications
    • Adverse reactions
    • Drug interactions
    • Description
    • Pharmacology
    • How supplied/storage & handling
    • Data source
    Prescribing Information
    Indications & Usage

    INDICATIONS AND USAGE

    For relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.

    Dosage & Administration

    DOSAGE AND ADMINISTRATION

    Adults and pediatric patients 12 years of age and over: 10 mL (2 teaspoonfuls) every 4 hours. Children 6 to under 12 years of age: 5 mL (1 teaspoonful) every 4 hours. Children 2 to under 6 years of age: 2.5 mL (½ teaspoonful) every 4 hours. Infants 6 months to under 2 years of age: Dosage to be established by a physician.


    Do not exceed 6 doses during a 24-hour period.

    Contraindications

    CONTRAINDICATIONS

    Hypersensitivity to any of the ingredients. Do not use in the newborn, in premature infants, in nursing mothers, or in patients with severe hypertension or severe coronary artery disease. Do not use dextromethorphan in patients receiving monoamine oxidase (MAOI) inhibitors (see PRECAUTIONS - Drug Interactions).


    Antihistamines should not be used to treat lower respiratory tract conditions including asthma.

    Adverse Reactions

    ADVERSE REACTIONS

    The most frequent adverse reactions to brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup are: sedation; dryness of mouth, nose and throat; thickening of bronchial secretions; dizziness. Other adverse reactions may include:


    Dermatologic: Urticaria, drug rash, photosensitivity, pruritus.


    Cardiovascular System : Hypotension, hypertension, cardiac arrhythmias, palpitation.


    CNS: Disturbed coordination, tremor, irritability, insomnia, visual disturbances, weakness, nervousness, convulsions, headache, euphoria, and dysphoria.


    G.U. System: Urinary frequency, difficult urination.


    G.I. System: Epigastric discomfort, anorexia, nausea, vomiting, diarrhea, constipation.


    Respiratory System: Tightness of chest and wheezing, shortness of breath.


    Hematologic System: Hemolytic anemia, thrombocytopenia, agranulocytosis.

    Drug Interactions

    Drug Interactions

    Monoamine oxidase (MAO) inhibitors
    Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS).


    Central nervous system (CNS) depressants
    Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.)


    Antihypertensive drugs
    Sympathomimetic may reduce the effects of antihypertensive drugs.

    Description

    DESCRIPTION

    Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup, 2 mg/30 mg/10 mg per 5 mL is a clear, light pink syrup with a butterscotch flavour.


    Each 5 mL (1 teaspoonful) contains:
    Brompheniramine Maleate, USP 2 mg
    Pseudoephedrine Hydrochloride, USP 30 mg
    Dextromethorphan Hydrobromide, USP 10 mg
    Alcohol 0.95% v/v
    In a palatable, aromatic vehicle.


    Inactive Ingredients: artificial butterscotch flavor, citric acid anhydrous, alcohol, FD&C Red No. 40, glycerin, sucrose, methylparaben, propylene glycol, purified water and sodium benzoate. It may contain 10% citric acid solution or 10% sodium citrate solution for pH adjustment. The pH range is between 4.0 and 6.0.


    Referenced Image


    Brompheniramine Maleate, USP(±)-2- p -Bromo-α-2-(dimethylamino)ethylbenzylpyridine maleate (1:1)


    Referenced Image



    Pseudoephedrine Hydrochloride, USP (+)-Pseudoephedrine hydrochloride

    Referenced Image



    Dextromethorphan Hydrobromide, USP 3-Methoxy-17-methyl-9α, 13α, 14α-morphinan hydrobromide monohydrate

    Antihistamine/Nasal Decongestant/Antitussive syrup for oral administration.

    Pharmacology

    CLINICAL PHARMACOLOGY

    Brompheniramine maleate is a histamine antagonist, specifically an H1-receptor-blocking agent belonging to the alkylamine class of antihistamines. Antihistamines appear to compete with histamine for receptor sites on effector cells. Brompheniramine also has anticholinergic (drying) and sedative effects. Among the antihistaminic effects, it antagonizes the allergic response (vasodilation, increased vascular permeability, increased mucus secretion) of nasal tissue. Brompheniramine is well absorbed from the gastrointestinal tract, with peak plasma concentration after single, oral dose of 4 mg reached in 5 hours; urinary excretion is the major route of elimination, mostly as products of biodegradation; the liver is assumed to be the main site of metabolic transformation.


    Pseudoephedrine acts on sympathetic nerve endings and also on smooth muscle, making it useful as a nasal decongestant. The nasal decongestant effect is mediated by the action of pseudoephedrine on α- sympathetic receptors, producing vasoconstriction of the dilated nasal arterioles. Following oral administration, effects are noted within 30 minutes with peak activity occurring at approximately one hour.


    Dextromethorphan acts centrally to elevate the threshold for coughing. It has no analgesic or addictive properties. The onset of antitussive action occurs in 15 to 30 minutes after administration and is of long duration.

    How Supplied/Storage & Handling

    HOW SUPPLIED

    Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup is a clear, light pink-colored, butterscotch-flavored syrup containing in each 5 mL (1 teaspoonful) brompheniramine maleate 2 mg, pseudoephedrine hydrochloride 30 mg and dextromethorphan hydrobromide 10 mg, available in the following sizes:


    4 fl oz (118 mL)                             NDC 71930-026-18
    1 pint (473 mL)                              NDC 71930-026-43


    RECOMMENDED STORAGE
    Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].


    KEEP TIGHTLY CLOSED


    Dispense in a tight, light-resistant container as defined in the USP


    Rx Only


    Manufactured by:
    WES Pharma Inc
    Westminster, MD – 21157
    USA


    Distributed by:
    Eywa Pharma Inc.,
    2 Research Way, Floor 3,
    Princeton, NJ 08540


    REV. 04/20

    Data SourceWe receive information directly from the FDA and PrescriberPoint is updated as frequently as changes are made available
    Report Adverse Event
    Interactions Banner
    Check medication interactionsReview interactions as part of your prescribing workflow

    Brompheniramine Maleate, Pseudoephedrine Hydrochloride, - Brompheniramine Maleate, Pseudoephedrine Hydrochloride, syrup PubMed™ news

      Show the latest PubMed™ articles for Brompheniramine Maleate, Pseudoephedrine Hydrochloride, - Brompheniramine Maleate, Pseudoephedrine Hydrochloride, syrup